Corvus Pharmaceuticals announces initiation of Phase 2 trial of soquelitinib

Corvus Pharmaceuticals (CRVS) announced that the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, NIH, has initiated a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome, ALPS, a rare genetic disease. The lead investigator of the trial is V. Koneti Rao, MD, FRCPA, Senior Research Physician, Primary Immune Deficiency Clinic at NIH Clinical Center. Dr. Rao previously presented preclinical data supporting the potential of soquelitinib in patients with ALPS. Other trial sites include Children’s Hospital of Philadelphia and Texas Children’s Cancer and Hematology Center.